Genetic Technologies to Hold Investor Webinar and Q&A Session on December 18
December 17 2019 - 9:00AM
Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE,
“Company”) is pleased to announce its interim-CEO, Dr. Jerzy
Muchnicki, will share insight into the company’s recent
developments during an investor webinar on December 18, 2019 at
4:00 p.m. ET. A live Q&A session with Dr. Muchnicki will follow
the presentation.
To participate in the webinar, please register at:
https://www.redchip.com/corporate/webinar_register/50
Questions can be pre-submitted to victor@redchip.com or on the
website during the event.
About Genetic Technologies Limited
Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a
diversified molecular diagnostics company. GTG offers cancer
predictive testing and assessment tools to help physicians
proactively manage patient health. The Company’s lead
products GeneType for Breast
Cancer and GeneType for Colorectal
Cancer are clinically validated risk assessment tests
and are first in class.
Genetic Technologies is developing a pipeline of risk assessment
products.
For more information, please
visit www.gtglabs.com
Cautionary Note Regarding Forward-Looking
Statements
Certain statements in this press release constitute
“forward-looking statements,” within the meaning of federal
securities laws, including statements related to the Company’s
anticipated use of proceeds and plans and prospects and other
statements containing the words “anticipate,” “intend,” “may,”
“plan,” “predict,” “will,” “would,” “could,” “should,” and similar
expressions, constitute forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995.
The Company's actual results could differ materially from those
anticipated in these forward-looking statements as a result of
various factors. Factors that could cause future results to
materially differ from the recent results or those projected in
forward-looking statements include the known risks, uncertainties
and other factors described in the Company’s prior filings and from
time to time in the Company’s subsequent filings with the
Securities and Exchange Commission. Any change in such factors,
risks and uncertainties may cause the actual results, events and
performance to differ materially from those referred to in such
statements. All information in this press release is as of the date
of the release and the Company does not undertake any duty to
update this information, including any forward-looking statements,
unless required by law.
FOR FURTHER INFORMATION PLEASE CONTACT
Investor Relations and Media (US) Dave Gentry,
CEO RedChip Companies Office: 1 800 RED CHIP (733 2447) Cell: US
407 491 4498 dave@redchip.com
Genetic Technologies (NASDAQ:GENE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genetic Technologies (NASDAQ:GENE)
Historical Stock Chart
From Apr 2023 to Apr 2024